AVE REVENUES DOUBLE IN SECOND QUARTER TO $38 MIL. AS FIRM LOGS $3 MIL. IN U.S. STENT SALES FOLLOWING DEC. 23 APPROVAL; J&J FOURTH QUARTER SALES UP 2.3%
This article was originally published in The Gray Sheet
Arterial Vascular Engineering's $2.9 mil. in initial U.S. sales of the Micro Stent II coronary stent just one week after FDA approval Dec. 23, coupled with strong international stent volume, was the driving force behind a 110% jump in corporate revenues to $38.3 mil. for the second quarter ended Dec. 31.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.